We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+14.15%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$736M
AUM Growth
+$94.9M
Cap. Flow
+$68.2M
Cap. Flow %
9.27%
Top 10 Hldgs %
43.9%
Holding
93
New
21
Increased
19
Reduced
26
Closed
17

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$30.8M
2
CRL icon
Charles River Laboratories
CRL
+$27.9M
3
LLY icon
Eli Lilly
LLY
+$25.6M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$20.8M
5
NVST icon
Envista
NVST
+$18.2M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$14.8M
2
ANAB icon
AnaptysBio
ANAB
+$13.6M
3
UTHR icon
United Therapeutics
UTHR
+$13.6M
4
ANGO icon
AngioDynamics
ANGO
+$13M
5
APEN
Apollo Endosurgery, Inc.
APEN
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.93%
2 Consumer Staples 4.27%
3 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NPCE icon
26
Neuropace
NPCE
$467M
$8.75M 1.19%
2,334,003
– –
VCEL icon
27
Vericel Corp
VCEL
$2.32B
$8.68M 1.18%
+374,000
New +$10.2M
PCVX icon
28
Vaxcyte
PCVX
$8.07B
$8.06M 1.09%
335,650
-35,000
-9% -$887K
CSTL icon
29
Castle Biosciences
CSTL
$929M
$7.77M 1.06%
+297,840
New +$8.35M
NARI
30
DELISTED
Inari Medical, Inc. Common Stock
NARI
$7.38M 1%
101,608
+29,310
+41% +$2.18M
TMDX icon
31
Transmedics
TMDX
$2.64B
$7.32M 0.99%
175,300
-9,155
-5% -$398K
HUM icon
32
Humana
HUM
$43.7B
$6.89M 0.94%
+14,200
New +$6.91M
NRIX icon
33
Nurix Therapeutics
NRIX
$2.61B
$6.57M 0.89%
504,144
-490,348
-49% -$7.76M
INBX
34
DELISTED
Inhibrx, Inc. Common Stock
INBX
$6.53M 0.89%
+363,902
New +$6.56M
ISRG icon
35
Intuitive Surgical
ISRG
$133B
$6.52M 0.89%
+34,800
New +$7.47M
ENTA icon
36
Enanta Pharmaceuticals
ENTA
$384M
$6.38M 0.87%
123,014
+23,014
+23% +$1.34M
APEN
37
DELISTED
Apollo Endosurgery, Inc.
APEN
$6.26M 0.85%
1,137,105
-2,131,843
-65% -$11.8M
BIIB icon
38
Biogen
BIIB
$30.5B
$6.19M 0.84%
+23,200
New +$4.93M
KROS icon
39
Keros Therapeutics
KROS
$198M
$5.49M 0.75%
+146,000
New +$5.06M
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$30.6B
$5.4M 0.73%
27,000
+6,900
+34% +$1.32M
ADVM
41
DELISTED
Adverum Biotechnologies
ADVM
$5.31M 0.72%
+558,779
New +$7.34M
AXGN icon
42
Axogen
AXGN
$2.43B
$5.07M 0.69%
+424,998
New +$4.25M
EPIX
43
DELISTED
ESSA Pharma
EPIX
$4.81M 0.65%
2,640,539
-1,528,260
-37% -$4.03M
PVLA
44
Palvella Therapeutics
PVLA
$2.22B
$4.75M 0.65%
51,686
– –
EXAS
45
DELISTED
Exact Sciences
EXAS
$4.71M 0.64%
144,800
+25,800
+22% +$1.06M
ENOV icon
46
Enovis
ENOV
$1.74B
$4.7M 0.64%
+102,100
New +$5.53M
CELC icon
47
Celcuity
CELC
$4.53B
$4.46M 0.61%
443,912
+25,000
+6% +$236K
XENE icon
48
Xenon Pharmaceuticals
XENE
$6.22B
$3.49M 0.47%
96,800
+21,800
+29% +$784K
ESTA icon
49
Establishment Labs
ESTA
$2.69B
$3.42M 0.46%
62,620
-15,780
-20% -$943K
NVRO
50
DELISTED
NEVRO CORP.
NVRO
$3.35M 0.46%
+72,000
New +$3.34M
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Soleus Capital Management held 93 positions worth $736M, up 15% from $641M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Soleus Capital Management deployed $68.2M of net new capital in Q3 2022, opening 21 new positions and adding to 19 existing holdings. Its largest new stake was Illumina: 155,845 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Viridian Therapeutics, an estimated $14.8M trimmed.

  • Soleus Capital Management's largest Q3 2022 buy was Illumina: 155,845 shares worth $28.9M.
  • Soleus Capital Management added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $20.8M increase.
  • Soleus Capital Management's biggest Q3 2022 reduction was Viridian Therapeutics, cutting an estimated $14.8M.
  • Soleus Capital Management fully exited AngioDynamics in Q3 2022, selling an estimated $13M.
  • Soleus Capital Management's ten largest holdings make up 44% of its $736M portfolio in Q3 2022.
  • Soleus Capital Management opened 21 new positions and closed 17 in Q3 2022.
  • Soleus Capital Management's portfolio value rose 15% quarter-over-quarter to $736M.

Based on Soleus Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.